1921
Volume 99, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Human immunodeficiency virus/tuberculosis (HIV/TB) coinfection is particularly prevalent in South Africa, where TB has been the leading cause of death for more than a decade. The 2004–2008 national rollout of antiretroviral therapy (ART) provides a unique opportunity to examine the population-level impact of ART on the TB epidemic. We performed longitudinal regression analysis to follow the evolution of TB outcomes before and after the introduction of ART using a large data set from the National Health Laboratory Service. This is the first study to produce estimates of the impact of the ART rollout by exploiting staggered timing and geographic variation in the rollout. After ART became available in a health facility, 3.7% ( < 0.0001) more patients were tested for TB and 3.2% ( < 0.0001) more received repeat testing; however, there was a steep rise in testing before the introduction of ART. Although the number of TB-positive patients increased by 4.3% ( = 0.0002) in the first year post-ART, the TB rate among tested patients fell by 2 percentage points (8%, = 0.001) after 2 years. Sputum smear testing declined relative to more technologically advanced diagnostics post-ART. Antiretroviral therapy availability increased the attention to TB screening and drew new patients into the health-care system. Small increases in the numbers of repeat patients are indicative of retention in care. The decline in TB rates post-ART suggests that the reduction in TB risk due to improved immune functioning and health-care contact likely outweighed the increased TB risk because of the longer lifespan of ART initiators.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0530
2018-10-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/6/tpmd170530.html?itemId=/content/journals/10.4269/ajtmh.17-0530&mimeType=html&fmt=ahah

References

  1. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S, , 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191: 150158. [Google Scholar]
  2. Getahun H, Gunneberg C, Granich R, Nunn P, , 2010. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50: S201S207. [Google Scholar]
  3. WHO, 2017. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization.
  4. Statistics South Africa, 2013. Mortality and Causes of Death in South Africa, 2010: Findings from Death Notification. Pretoria, South Africa: Statistics South Africa. Available at: http://www.statssa.gov.za/publications/p03093/p030932010.PDF. Accessed September 17, 2015.
  5. Bor J, Herbst AJ, Newell ML, Bärnighausen T, , 2013. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961965. [Google Scholar]
  6. Nanoo A, Izu A, Ismail NA, Ihekweazu C, Abubakar I, Mametja D, Madhi SA, , 2015. Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in South Africa, 2004–12: a time series analysis. Lancet Infect Dis 15: 10661076. [Google Scholar]
  7. McLaren ZM, , 2015. Equity in the national rollout of public AIDS treatment in South Africa 2004–08. Health Policy Plan 30: 11621172. [Google Scholar]
  8. Johnson LF, , 2012. Access to antiretroviral treatment in South Africa, 2004–2011. South Afr J HIV Med 13: 2226. [Google Scholar]
  9. Havlir DV, Getahun H, Sanne I, Nunn P, , 2008. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 300: 423430. [Google Scholar]
  10. Abdool Karim SS, 2011. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 14921501. [Google Scholar]
  11. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R, , 2011. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 15: 571581. [Google Scholar]
  12. Karim SS, Churchyard GJ, Karim QA, Lawn SD, , 2009. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374: 921933. [Google Scholar]
  13. McLaren ZM, Sharp AR, Zhou J, Wasserman S, Nanoo A, , 2017. Assessing healthcare quality using routine data: evaluating the performance of the national tuberculosis programme in South Africa. Trop Med Int Health 22: 171179. [Google Scholar]
  14. Wood R, Lawn SD, , 2011. Antiretroviral treatment as prevention: impact of the ‘test and treat’ strategy on the tuberculosis epidemic. Curr HIV Res 9: 383392. [Google Scholar]
  15. Girardi E, Antiretroviral Therapy Cohort Collaboration , 2005. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 41: 17721782. [Google Scholar]
  16. Middelkoop K, Bekker LG, Myer L, Whitelaw A, Grant A, Kaplan G, McIntyre J, Wood R, , 2010. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 182: 10801085. [Google Scholar]
  17. Pretorius C, 2014. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models. AIDS 28: S25S34. [Google Scholar]
  18. Suthar AB, 2012. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9: e1001270. [Google Scholar]
  19. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C, , 2010. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 107: 1948519489. [Google Scholar]
  20. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA, , 2010. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 51: 823829. [Google Scholar]
  21. Zachariah R, 2011. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis 15: 933937. [Google Scholar]
  22. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S, , 2006. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43: 4246. [Google Scholar]
  23. April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP, , 2014. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis 209: 491499. [Google Scholar]
  24. National Treasury South Africa, 2007. Provincial Budgets and Expenditure Review: 2003/04–2009/10. Pretoria, South Africa. Available at: http://www.treasury.gov.za/publications/igfr/2007/prov/00.%20Front%20Pages%20and%20Contents.PDF. Accessed September 17, 2015.
  25. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S, , 2012. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7: e36966. [Google Scholar]
  26. Rosen S, Ketlhapile M, Sanne I, DeSilva MB, , 2008. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic) 7: 200207. [Google Scholar]
  27. World Health Organization, 2008. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization.
  28. Houben RM, Glynn JR, Mboma S, Mzemba T, Mwaungulu NJ, Mwaungulu L, Mwenibabu M, Mpunga J, French N, Crampin AC, , 2012. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. AIDS 26: 22332239. [Google Scholar]
  29. Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG, , 2013. Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis. PLoS One 8: e75466. [Google Scholar]
  30. Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, Wiysonge CS, Mataya RH, , 2007. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in southern Africa: a systematic review. BMC Public Health 7: 63. [Google Scholar]
  31. Wouters E, Heunis C, Ponnet K, Van Loon F, le Roux Booysen F, van Rensburg D, Meulemans H, , 2010. Who is accessing public-sector anti-retroviral treatment in the Free State, South Africa? An exploratory study of the first three years of programme implementation. BMC Public Health 10: 387. [Google Scholar]
  32. Reid MJ, Shah NS, , 2009. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 9: 173184. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0530
Loading
/content/journals/10.4269/ajtmh.17-0530
Loading

Data & Media loading...

  • Received : 03 Jul 2017
  • Accepted : 31 May 2018
  • Published online : 01 Oct 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error